Establishment of VCA and EBNA1 IgA‐based combination by enzyme‐linked immunosorbent assay as preferred screening method for nasopharyngeal carcinoma: a two‐stage design with a preliminary performance study and a mass screening in southern China

A two‐stage study was conducted in southern China to determine and validate an optimal combination of Epstein‐Barr virus (EBV)‐related seromarkers for nasopharyngeal carcinoma (NPC) screening. In the first stage, six seromarkers [VCA‐IgA, EA‐IgA, Epstein‐Barr virus nuclear antigen 1 (EBNA1‐IgA), EBNA1‐IgG, Zta‐IgA and Rta‐IgG] were detected by enzyme‐linked immunosorbent assay (ELISA) and two traditional NPC screening seromarkers (VCA‐IgA and EA‐IgA) were detected by immunofluorescence assay (IFA) in serum samples from 191 NPC patients and 337 controls. An optimal combination of seromarkers for NPC diagnosis was selected using logistic regression models. Results showed that the diagnostic performances of VCA‐IgA and EA‐IgA tested by ELISA were superior to the performances of the same seromarkers by IFA. VCA‐IgA combined with EBNA1‐IgA by ELISA was identified as the optimal combination, with an area under the receiver operating characteristic (ROC) curve (AUC) up to 0.97, a sensitivity of 95.3% and a specificity of 94.1% for classification of NPCs vs. controls. In the second stage, 5,481 participants aged 30–59 years and without clinical evidence of NPC were recruited into a population‐based NPC screening program from May 2008 to February 2009 in Sihui City, China. Their sera were tested simultaneously by both the new and the traditional screening schemes and eight early stage NPC patients were subsequently histopathologically confirmed. The traditional and the new screening schemes had comparable specificity (estimated as 98.5%), but the sensitivity of the new scheme (75.0%) was significantly higher than that of the traditional one (25.0%). The combination of VCA‐IgA and EBNA1‐IgA by ELISA outperforms the traditional NPC screening scheme and could become the preferred serodiagnostic strategy for NPC screening in high‐incidence areas.

[1]  W. Jia,et al.  Fluctuations of Epstein-Barr Virus Serological Antibodies and Risk for Nasopharyngeal Carcinoma: A Prospective Screening Study with a 20-Year Follow-Up , 2011, PloS one.

[2]  Chien-Jen Chen,et al.  Screening and Early Diagnosis of Nasopharyngeal Carcinoma , 2010 .

[3]  W. Jia,et al.  Clinical values of multiple Epstein-Barr virus (EBV) serological biomarkers detected by xMAP technology , 2009, Journal of Translational Medicine.

[4]  L. Gaffikin,et al.  Avoiding verification bias in screening test evaluation in resource poor settings: a case study from Zimbabwe , 2008, Clinical trials.

[5]  J. Tang,et al.  Evaluation of Epstein-Barr virus antigen-based immunoassays for serological diagnosis of nasopharyngeal carcinoma. , 2007, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[6]  H. Adami,et al.  The Enigmatic Epidemiology of Nasopharyngeal Carcinoma , 2006, Cancer Epidemiology Biomarkers & Prevention.

[7]  H. Adami,et al.  Trends in incidence and mortality of nasopharyngeal carcinoma over a 20–25 year period (1978/1983–2002) in Sihui and Cangwu counties in southern China , 2006, BMC Cancer.

[8]  Jaap M Middeldorp,et al.  Single-Assay Combination of Epstein-Barr Virus (EBV) EBNA1- and Viral Capsid Antigen-p18-Derived Synthetic Peptides for Measuring Anti-EBV Immunoglobulin G (IgG) and IgA Antibody Levels in Sera from Nasopharyngeal Carcinoma Patients: Options for Field Screening , 2006, Journal of Clinical Microbiology.

[9]  B. H. Patterson,et al.  Evaluating markers for the early detection of cancer: overview of study designs and methods , 2006, Clinical trials.

[10]  J. Daoud,et al.  Comparison of three different serological techniques for primary diagnosis and monitoring of nasopharyngeal carcinoma in two age groups from Tunisia , 2005, Journal of medical virology.

[11]  C. Sam,et al.  Epstein-Barr virus serology in the diagnosis of nasopharyngeal carcinoma. , 2005, Asian Pacific journal of allergy and immunology.

[12]  P. Prorok,et al.  Development Tracks for Cancer Prevention Markers , 2004, Disease markers.

[13]  S. Leung,et al.  Improved accuracy of detection of nasopharyngeal carcinoma by combined application of circulating Epstein-Barr virus DNA and anti-Epstein-Barr viral capsid antigen IgA antibody. , 2004, Clinical chemistry.

[14]  Xiao-Hua Zhou,et al.  Adjusting for non‐ignorable verification bias in clinical studies for Alzheimer's disease , 2004, Statistics in medicine.

[15]  M. Stolzenberg,et al.  Relationship between antibody production to Epstein-Barr virus (EBV) early antigens and various EBV-related diseases , 2004, Springer Seminars in Immunopathology.

[16]  Huiman X Barnhart,et al.  A global sensitivity analysis of performance of a medical diagnostic test when verification bias is present , 2003, Statistics in medicine.

[17]  W. Hammerschmidt,et al.  The EBV nuclear antigen 1 (EBNA1) enhances B cell immortalization several thousandfold , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[18]  J. Sham,et al.  EBV specific antibody‐based and DNA‐based assays in serologic diagnosis of nasopharyngeal carcinoma , 2003, International journal of cancer.

[19]  Jian-Min Yuan,et al.  Epidemiology of nasopharyngeal carcinoma. , 2002, Seminars in cancer biology.

[20]  S. Tsuchiya.  Diagnosis of Epstein-Barr virus-associated diseases. , 2002, Critical reviews in oncology/hematology.

[21]  Kwok-Hung Chan,et al.  Assessing the risk of nasopharyngeal carcinoma on the basis of EBV antibody spectrum , 2002, International journal of cancer.

[22]  S. Chan,et al.  Antibody response to Epstein–Barr virus Rta protein in patients with nasopharyngeal carcinoma , 2001, Cancer.

[23]  A. Benider,et al.  Antibody Responses to Recombinant Epstein-Barr Virus Antigens in Nasopharyngeal Carcinoma Patients: Complementary Test of ZEBRA Protein and Early Antigens p54 and p138 , 2001, Journal of Clinical Microbiology.

[24]  M. Hsu,et al.  Specific IgA antibodies to recombinant early and nuclear antigens of Epstein-Barr virus in nasopharyngeal carcinoma. , 2001, Clinical otolaryngology and allied sciences.

[25]  M S Pepe,et al.  Phases of biomarker development for early detection of cancer. , 2001, Journal of the National Cancer Institute.

[26]  Chien-Jen Chen,et al.  Use of bacterially expressed EBNA‐1 protein cloned from a nasopharyngeal carcinoma (NPC) biopsy as a screening test for NPC patients , 2001, Journal of medical virology.

[27]  Jun Ma,et al.  A comparison of the Chinese 1992 and fifth‐edition International Union Against Cancer staging systems for staging nasopharyngeal carcinoma , 2000, Cancer.

[28]  J. Butler.  Enzyme-Linked Immunosorbent Assay , 2000, Journal of immunoassay.

[29]  Hui-min Wang,et al.  Establishment of high risk population and precancerous lesion of nasopharyngeal carcinoma (NPC) , 1997 .

[30]  Y. Gan,et al.  Epstein-Barr Viral Antigens Used in the Diagnosis of Nasopharyngeal Carcinoma. , 1996, Journal of biomedical science.

[31]  K. McGraw,et al.  Forming inferences about some intraclass correlation coefficients. , 1996 .

[32]  Y. F. Poon,et al.  A possible prognostic role of immunoglobulin‐G antibody against recombinant Epstein‐Barr virus BZLF‐1 transactivator protein ZEBRA in patients with nasopharyngeal carcinoma , 1994, Cancer.

[33]  L. Sobin,et al.  The world health organization histological classification of tumours of the upper respiratory tract and ear. A commentary on the second edition , 1993, Cancer.

[34]  M. Perricaudet,et al.  Detection of anti‐epstein‐barr‐virus transactivator (ZEBRA) antibodies in sera from patients with nasopharyngeal carcinoma , 1991, International journal of cancer.

[35]  K. Shanmugaratnam.  Histological Classification of Tumours of the Upper Respiratory Tract and Ear , 1991 .

[36]  G. Samsa,et al.  Likelihood ratios with confidence: sample size estimation for diagnostic test studies. , 1991, Journal of clinical epidemiology.

[37]  C. J. Chen,et al.  Multiple risk factors of nasopharyngeal carcinoma: Epstein-Barr virus, malarial infection, cigarette smoking and familial tendency. , 1990, Anticancer research.

[38]  J. Fleiss.  The design and analysis of clinical experiments , 1987 .

[39]  A. Scott,et al.  Enzyme-linked immunosorbent assay of antibodies to Epstein-Barr virus nuclear and early antigens in patients with infectious mononucleosis and nasopharyngeal carcinoma. , 1986, Annals of internal medicine.

[40]  N E Day,et al.  Estimating the sensitivity of a screening test. , 1985, Journal of epidemiology and community health.

[41]  Z. Jisong,et al.  Application of an immunoenzymatic method and an immunoautoradiographic method for a mass survey of nasopharyngeal carcinoma. , 1980, Intervirology.

[42]  W. Henle,et al.  Epstein‐barr virus‐specific IgA serum antibodies as an outstanding feature of nasopharyngeal carcinoma , 1976, International journal of cancer.

[43]  Dr Ferdiye Taner,et al.  The enzyme-linked immunosorbent assay (ELISA). , 1976, Bulletin of the World Health Organization.

[44]  D. Rubin.  INFERENCE AND MISSING DATA , 1975 .

[45]  E. Engvall,et al.  Enzyme-linked immunosorbent assay, Elisa. 3. Quantitation of specific antibodies by enzyme-labeled anti-immunoglobulin in antigen-coated tubes. , 1972, Journal of immunology.

[46]  L. Old,et al.  PRECIPITATING ANTIBODY IN HUMAN SERUM TO AN ANTIGEN PRESENT IN CULTURED BURKITT'S LYMPHOMA CELLS* , 1966, Proceedings of the National Academy of Sciences of the United States of America.